# Scailyte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scailyte

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.scailyte.com
- Total disclosed funding: $9.3M
- Latest round: Series A (Jan 10, 2022)
- Investors on record: 4

## About

Based in Basel, Switzerland, and founded in 2017 by CEO Peter Nestorov, Daniel Sonnleithner, Dennis Gohlsdorf, and Manfred Claassen, Scailyte AG, a.k.a. Scailyte, operates as a developer of precision medicine for disease patterns from single-cell data. In January 2024, Hera Biotech, Inc., a portfolio company of Coyote Ventures, Althea Group Ventures, Kendra Scott Women’s Entrepreneurial Leadership Institute, and Stella Angels agreed to acquire Scailyte AG from Mirabaud Asset Management, Swisscom Ventures, Venture Kick, 4FO Ventures, Zürcher Kantonalbank, investiere, and Hemex AG.

Scailyte specializes in discovering predictive biomarkers and designing companion diagnostics in immunology and oncology using single-cell omics and AI. The company’s AI discovery platform, ScaiVision, enables precise biomarker identification for improved therapy responses and disease diagnosis.

The company plans to use its proceeds from the January 2024 acquisition to expand its diagnostic programs for endometriosis.

## Funding rounds

- Series A, Jan 10, 2022, $6.5M — Swisscom Ventures, Mirabaud Asset Management
- Seed, Dec 19, 2018, $2.8M — Zürcher Kantonalbank, Swisscom Ventures, Venture Kick

## Investors

- Zürcher Kantonalbank — Seed
- Swisscom Ventures (https://capitalatlas.ai/funds/swisscom-ventures) — Seed, Series A
- Venture Kick (https://capitalatlas.ai/funds/venture-kick) — Seed
- Mirabaud Asset Management (https://capitalatlas.ai/funds/mirabaud-asset-management) — Series A